CPC A61M 5/007 (2013.01) [A61K 51/121 (2013.01); A61K 51/1282 (2013.01); A61M 5/142 (2013.01); A61M 5/1408 (2013.01); A61M 5/162 (2013.01); A61M 5/16827 (2013.01); A61M 5/16881 (2013.01); A61N 5/1007 (2013.01); G01T 1/20 (2013.01); G01T 7/005 (2013.01); G21F 5/015 (2013.01); G21G 1/0005 (2013.01); G21G 4/08 (2013.01); G21H 5/02 (2013.01); A61K 2123/00 (2013.01); A61M 2205/18 (2013.01); A61M 2205/3313 (2013.01); A61M 2205/3389 (2013.01); A61M 2205/702 (2013.01); A61N 2005/1021 (2013.01); G01T 1/1603 (2013.01); G21G 2001/0031 (2013.01)] | 38 Claims |
1. An infusion system comprising:
a frame that carries a beta detector, a gamma detector, and a controller communicatively coupled to the beta detector and the gamma detector,
wherein the frame is further configured to receive a strontium-rubidium radioisotope generator that generates a radioactive eluate via elution,
the beta detector is positioned to measure beta emissions emitted from the radioactive eluate,
the gamma detector is positioned to measure gamma emissions emitted from the radioactive eluate, and
the controller is configured to determine an activity of rubidium in the radioactive eluate based on the beta emissions measured by the beta detector and determine an activity of strontium in the radioactive eluate based on the gamma emissions measured by the gamma detector.
|